Akoya Biosciences (AKYA)
(Real Time Quote from BATS)
$3.91 USD
+0.06 (1.56%)
Updated Apr 19, 2024 10:22 AM ET
3-Hold of 5 3
D Value B Growth C Momentum C VGM
Income Statements
Fiscal Year end for Akoya Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 97 | 75 | 55 | 42 | 42 |
Cost Of Goods | 40 | 31 | 21 | 17 | 18 |
Gross Profit | 56 | 43 | 34 | 26 | 25 |
Selling & Adminstrative & Depr. & Amort Expenses | 114 | 109 | 74 | 38 | 37 |
Income After Depreciation & Amortization | -58 | -66 | -39 | -12 | -12 |
Non-Operating Income | 3 | 0 | -1 | -2 | 0 |
Interest Expense | 9 | 5 | 3 | 3 | 2 |
Pretax Income | -63 | -71 | -43 | -17 | -15 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -63 | -71 | -43 | -17 | -15 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -63 | -71 | -43 | -17 | -15 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -49 | -59 | -35 | -8 | -9 |
Depreciation & Amortization (Cash Flow) | 9 | 7 | 5 | 4 | 3 |
Income After Depreciation & Amortization | -58 | -66 | -39 | -12 | -12 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 44.44 | 37.75 | 26.90 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.43 | -1.87 | -1.64 | NA | NA |
Diluted Net EPS (GAAP) | -1.43 | -1.87 | -1.65 | -9.18 | NA |
Fiscal Year end for Akoya Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 26.49 | 25.22 | 23.52 | 21.41 |
Cost Of Goods | NA | 9.87 | 9.94 | 11.41 | 9.12 |
Gross Profit | NA | 16.62 | 15.28 | 12.12 | 12.29 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 26.06 | 26.83 | 31.36 | 29.73 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -9.44 | -11.55 | -19.24 | -17.44 |
Non-Operating Income | NA | 0.91 | 0.89 | 0.63 | 0.72 |
Interest Expense | NA | 2.29 | 2.24 | 2.18 | 2.05 |
Pretax Income | NA | -10.82 | -12.90 | -20.79 | -18.77 |
Income Taxes | NA | -0.02 | 0.02 | 0.02 | 0.03 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -10.80 | -12.92 | -20.80 | -18.80 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -10.80 | -12.92 | -20.80 | -18.80 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 49.09 | 48.98 | 40.64 | 38.33 |
Diluted EPS Before Non-Recurring Items | NA | -0.22 | -0.26 | -0.51 | -0.49 |
Diluted Net EPS (GAAP) | NA | -0.17 | -0.26 | -0.51 | -0.49 |